NCT05606692View on ClinicalTrials.gov

Influences of Propofol and Sevoflurane Anesthesia in Ovarian Cancer (Anesthetics)

PHASE4RecruitingINTERVENTIONAL

Enrollment

416

Participants

Timeline

Start Date

November 23, 2022

Primary Completion Date

September 30, 2026

Study Completion Date

September 30, 2027

Conditions

Ovarian Cancer

Interventions

DRUG

Propofol 1%

The propofol group was both induced and maintained at an effect-site concentration (Ce) of 2.0-4.0 mcg/mL by a target-controlled infusion (TCI) system.

DRUG

Sevoflurane/Ultane

The sevoflurane group was maintained via sevoflurane vaporizer between 1% and 3% (target minimum alveolar concentration of 0.7-1.3).

Trial Locations (1)

Unknown

RECRUITING

Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung City

All Listed Sponsors

collaborator

Tri-Service General Hospital

OTHER

lead

Kaohsiung Medical University Chung-Ho Memorial Hospital

OTHER

NCT05606692 - Influences of Propofol and Sevoflurane Anesthesia in Ovarian Cancer (Anesthetics) | Biotech Hunter | Biotech Hunter